| 产品描述: | ND3229 是一种可逆性的 EGFRC797S 抑制剂,对 EGFRL858R/T790M/C797S、EGFRWT 和 EGFRL858R/T790M 的 IC50 值分别为 5.8、6.8 和 30.5 nM。JND3229 具有较好的抗增殖活性,能有效地抑制体内肿瘤的生长。JND3229 可用于癌症,尤其是非小细胞癌的研究 |
| 靶点: |
IC50: 5.8 nM (EGFRL858R/T790M/C797S), 6.8 nM (EGFRWT), 30.5 nM (EGFRL858R/T790M)。;EGFR |
| 体外研究: |
JND3229 potently inhibits the proliferation of BaF3 cells (harboring the EGFRL858R/T790M/C797S and EGFR19D/T790M/C797Smutations), NCI-H1975 NSCLC cells (with EGFRT790M mutation) and A431 cancer cells (overexpressing EGFRWT) with IC50 values of 0.51, 0.32, 0.31 and 0.27 µM, respectively[1]. JND3229 (0.1, 0.3, 1, 3, 10 µM; 2 h) potently inhibits the phosphorylation of EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S in engineering BaF3 cells. |
| 体内研究: |
JND3229 (10 mg/kg; i.p.; twice daily for 10 days) exhibits an obvious suppression of tumor growth, and shows target inhibition in vivo. |
| 参考文献: |
1.Lu X, et al. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127. |
| 溶解性: |
Souble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.62 ml |
8.101 ml |
16.203 ml |
| 5 mM |
0.324 ml |
1.62 ml |
3.241 ml |
| 10 mM |
0.162 ml |
0.81 ml |
1.62 ml |
| 50 mM |
0.032 ml |
0.162 ml |
0.324 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |